Rishdha Roshad: Activated Clotting Time – Adult vs Pediatric
Rishdha Roshad, BS Cardiac Perfusion Technology Student at Dow University of Health Sciences, shared a post on LinkedIn:
“One ACT target. Different patients. Different physiology.
Activated Clotting Time (ACT) is one of the most frequently monitored parameters during cardiopulmonary bypass.
Yet, it is often interpreted as a single number rather than a reflection of a patient’s unique physiology.
This raises an important question:
Why is an ACT ≥480 seconds generally acceptable for adult CPB, while pediatric patients often require different anticoagulation strategies—and sometimes even higher ACT targets?
The answer lies in the relationship between the patient and the extracorporeal circuit.
In adult cardiac surgery, the patient’s circulating blood volume is substantially larger than the circuit prime, resulting in comparatively less haemodilution.
Standard weight-based heparin dosing with ACT monitoring is usually sufficient to achieve safe anticoagulation.
In neonates and infants, however, the circuit prime may equal or even exceed the patient’s circulating blood volume.
This leads to profound haemodilution, dilution of coagulation factors and antithrombin, altered platelet function, and greater variability in the heparin response.
Consequently, many pediatric programs target ACT values between 480–600 seconds, often complemented by heparin concentration monitoring or viscoelastic coagulation testing.
Importantly, ACT is influenced by more than heparin alone.
Hypothermia, haemodilution, hematocrit, platelet dysfunction, antithrombin deficiency, thrombocytopenia, and even sampling technique can all affect the result.
ACT is not the goal—safe anticoagulation is.
For perfusionists, the responsibility extends beyond achieving a target value. It lies in understanding the physiology behind that value and integrating it with sound clinical judgment to ensure safe extracorporeal circulation.
Because in perfusion, we don’t treat numbers—we treat patients.”

Stay updated with Hemostasis Today.
-
Nov 17, 2026, 01:27X. Long Zheng: Optimizing Treatment in Immune TTP
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C